Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango

Author: Gupta Sahil   Weinstock-Guttman Bianca  

Publisher: Informa Healthcare

ISSN: 1471-2598

Source: Expert Opinion on Biological Therapy, Vol.14, Iss.1, 2014-01, pp. : 115-126

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract